CN1297553C - 制备核苷类似物的立体选择性方法 - Google Patents

制备核苷类似物的立体选择性方法 Download PDF

Info

Publication number
CN1297553C
CN1297553C CNB028159624A CN02815962A CN1297553C CN 1297553 C CN1297553 C CN 1297553C CN B028159624 A CNB028159624 A CN B028159624A CN 02815962 A CN02815962 A CN 02815962A CN 1297553 C CN1297553 C CN 1297553C
Authority
CN
China
Prior art keywords
alkyl
pyrimidine
formula
bromine
iodine
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CNB028159624A
Other languages
English (en)
Chinese (zh)
Other versions
CN1543463A (zh
Inventor
于庆
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Shire Canada Inc
Original Assignee
Shire Canada Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Shire Canada Inc filed Critical Shire Canada Inc
Publication of CN1543463A publication Critical patent/CN1543463A/zh
Application granted granted Critical
Publication of CN1297553C publication Critical patent/CN1297553C/zh
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D327/00—Heterocyclic compounds containing rings having oxygen and sulfur atoms as the only ring hetero atoms
    • C07D327/02—Heterocyclic compounds containing rings having oxygen and sulfur atoms as the only ring hetero atoms one oxygen atom and one sulfur atom
    • C07D327/04—Five-membered rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D411/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen and sulfur atoms as the only ring hetero atoms
    • C07D411/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen and sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D411/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen and sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Virology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
  • Saccharide Compounds (AREA)
  • Heterocyclic Compounds Containing Sulfur Atoms (AREA)
CNB028159624A 2001-06-15 2002-06-14 制备核苷类似物的立体选择性方法 Expired - Fee Related CN1297553C (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US29807901P 2001-06-15 2001-06-15
US60/298,079 2001-06-15

Publications (2)

Publication Number Publication Date
CN1543463A CN1543463A (zh) 2004-11-03
CN1297553C true CN1297553C (zh) 2007-01-31

Family

ID=23148927

Family Applications (1)

Application Number Title Priority Date Filing Date
CNB028159624A Expired - Fee Related CN1297553C (zh) 2001-06-15 2002-06-14 制备核苷类似物的立体选择性方法

Country Status (28)

Country Link
US (2) US7109334B2 (enExample)
EP (2) EP1632490B1 (enExample)
JP (1) JP4542776B2 (enExample)
KR (1) KR100832617B1 (enExample)
CN (1) CN1297553C (enExample)
AP (1) AP1559A (enExample)
AT (2) ATE313542T1 (enExample)
AU (2) AU2002344862C1 (enExample)
BR (2) BR0210444A (enExample)
CA (1) CA2449338C (enExample)
CO (1) CO5550497A2 (enExample)
CY (1) CY1107805T1 (enExample)
DE (2) DE60222031T2 (enExample)
DK (2) DK1632490T3 (enExample)
EA (1) EA006372B1 (enExample)
ES (2) ES2293445T3 (enExample)
HR (1) HRP20031021B1 (enExample)
IL (2) IL159139A0 (enExample)
MX (1) MXPA03011627A (enExample)
NO (1) NO326135B1 (enExample)
NZ (1) NZ529906A (enExample)
OA (1) OA12628A (enExample)
PL (2) PL215267B1 (enExample)
PT (1) PT1632490E (enExample)
RS (1) RS50868B (enExample)
SI (2) SI1406896T1 (enExample)
WO (1) WO2002102796A1 (enExample)
ZA (1) ZA200309307B (enExample)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7501514B1 (en) 2003-10-15 2009-03-10 Shire Biochem, Inc. Enantiomeric resolution of 2-substituted 4-substituted 1,3-oxathiolanes nucleosides
JP4653966B2 (ja) * 2004-04-19 2011-03-16 ダイセル化学工業株式会社 ２−ベンゾイルオキシアセトアルデヒド誘導体の製造法
WO2009039582A1 (en) * 2007-09-28 2009-04-02 Avexa Limited A process for chiral resolution of 2-substituted 4-substituted 1,3-oxathiolanes
US20130165350A1 (en) * 2011-12-22 2013-06-27 Affymetrix, Inc. Surface linkers for array synthesis

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5587480A (en) * 1990-11-13 1996-12-24 Biochem Pharma, Inc. Substituted 1,3-oxathiolanes and substituted 1,3-dithiolanes with antiviral properties

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR840001591A (ko) * 1981-09-29 1984-05-07 구라바야시 이꾸시로 당케탈류의 제조방법
ATE143016T1 (de) * 1990-11-13 1996-10-15 Iaf Biochem Int Substituierte 1,3-oxathiolane mit antiviralen eigenschaften
US5532349A (en) * 1993-07-20 1996-07-02 Mitsui Toatsu Chemicals, Inc. Process for producing 1-(2'-deoxy-β-D-erythro-pentofuranosyl)-5-trifluoromethyluracil derivatives
ES2232169T3 (es) * 1998-08-12 2005-05-16 Gilead Sciences, Inc. Procedimiento de fabricacion de nucleosidos de 1,3-oxatiolano.

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5587480A (en) * 1990-11-13 1996-12-24 Biochem Pharma, Inc. Substituted 1,3-oxathiolanes and substituted 1,3-dithiolanes with antiviral properties

Also Published As

Publication number Publication date
NZ529906A (en) 2006-03-31
DE60208202T2 (de) 2006-08-17
DK1632490T3 (da) 2008-01-28
DE60222031D1 (de) 2007-10-04
SI1406896T1 (sl) 2006-04-30
AU2002344862B2 (en) 2008-05-01
EA200400042A1 (ru) 2004-06-24
KR100832617B1 (ko) 2008-05-27
HK1070652A1 (en) 2005-06-24
KR20040017233A (ko) 2004-02-26
CO5550497A2 (es) 2005-08-31
ATE370945T1 (de) 2007-09-15
JP2004535428A (ja) 2004-11-25
HRP20031021A2 (en) 2004-06-30
WO2002102796A8 (en) 2003-09-18
PL218777B1 (pl) 2015-01-30
WO2002102796A1 (en) 2002-12-27
PL366907A1 (en) 2005-02-07
US20060183899A1 (en) 2006-08-17
HRP20031021B1 (hr) 2007-09-30
IL159139A (en) 2010-04-15
BR0210444A (pt) 2004-08-17
NO20035556D0 (no) 2003-12-12
BRPI0210444B1 (pt) 2017-06-20
NO326135B1 (no) 2008-10-06
JP4542776B2 (ja) 2010-09-15
AP1559A (en) 2006-01-24
YU97503A (sh) 2006-05-25
CA2449338A1 (en) 2002-12-27
SI1632490T1 (sl) 2008-02-29
PT1632490E (pt) 2007-11-07
DE60208202D1 (de) 2006-01-26
EP1632490B1 (en) 2007-08-22
EP1406896A1 (en) 2004-04-14
ZA200309307B (en) 2005-02-23
EP1406896B1 (en) 2005-12-21
PL215267B1 (pl) 2013-11-29
US7109334B2 (en) 2006-09-19
US7230100B2 (en) 2007-06-12
ES2293445T3 (es) 2008-03-16
ATE313542T1 (de) 2006-01-15
DK1406896T3 (da) 2006-05-08
US20030135048A1 (en) 2003-07-17
CA2449338C (en) 2012-02-07
OA12628A (en) 2006-06-13
CN1543463A (zh) 2004-11-03
EP1406896B8 (en) 2006-11-15
MXPA03011627A (es) 2005-03-07
IL159139A0 (en) 2004-06-01
AU2008203443B2 (en) 2011-06-16
EP1632490A1 (en) 2006-03-08
DE60222031T2 (de) 2008-05-21
EA006372B1 (ru) 2005-12-29
PL401835A1 (pl) 2013-02-18
CY1107805T1 (el) 2013-06-19
RS50868B (sr) 2010-08-31
AU2002344862C1 (en) 2009-02-19
AU2008203443A1 (en) 2008-08-21
ES2254695T3 (es) 2006-06-16

Similar Documents

Publication Publication Date Title
CN1045088C (zh) 用作pnp抑制剂的嘌呤和鸟嘌呤化合物
CN1290841C (zh) 核苷类似物的非对映选择合成方法
CN1036920C (zh) 含杂环碳酸衍生物
CN1122037C (zh) 噻吩并[2,3－d]嘧啶二酮类化合物及其制法、用途和含其的药物组合物
CN1173945C (zh) 5-硫代-ω-取代的苯基-前列腺素E衍生物、其制备方法及含有它们作为活性成分的药物
CN1176651C (zh) N-(3-苯并呋喃基)脲衍生物
CN1285842A (zh) 化合物
CN1229079A (zh) 非对映选择性合成核苷的方法中所使用的中间产物的制备方法
HK1046134A1 (en) Novel lipoic acid derivatives, their preparation, and pharmaceutical compositions containing them
CN1032361C (zh) 咪唑并哒嗪化合物的制备方法
CN1297553C (zh) 制备核苷类似物的立体选择性方法
CN1153766C (zh) 新的硝酮化合物，其制备方法以及含有它们的药物组合物
CN87107226A (zh) 内酰胺衍生物及其制备
CN1142929C (zh) 制备2-烷基-3-氨基噻吩衍生物的方法以及3-氨基噻吩衍生物
CN1273453C (zh) 生物素中间体及其制法
CN1383427A (zh) 制备n6－取代的脱氮杂一腺苷衍生物的方法
CN1665506A (zh) 作为ccr－3受体拮抗剂ⅸ的2,5－取代的嘧啶衍生物
HK1070652B (en) Stereoselective method for the preparation of nucleoside analogues
CN1054982A (zh) 取代的嘌呤，其制备方法以及作为抗病毒药的用途
CN1028531C (zh) 1-氧杂-2-氧代-8-氮杂螺[4，5]癸烷衍生物及其盐的制备方法
CN1035876C (zh) 四氢噻吩衍生物及其药物组合物
CN1185247C (zh) 吲哚吡咯并咔唑衍生物的制备方法、制备中的中间体以及制备中间体的方法
CN1064679A (zh) 醌类衍生物
CN1070397A (zh) 吲哚氨磺酰取代的二氢吡啶及其制法和药用
CN1680270A (zh) 3，4，5－三取代的苯丙烯类衍生物及其制备方法和用途

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 1070652

Country of ref document: HK

C14 Grant of patent or utility model
GR01 Patent grant
C56 Change in the name or address of the patentee

Owner name: SERGE CANADIAN CO., LTD.

Free format text: FORMER NAME OR ADDRESS: SHIRE BIOCHEM INC.

CP01 Change in the name or title of a patent holder

Address after: Quebec

Patentee after: Shire Biochem Inc.

Address before: Quebec

Patentee before: Serre Biological Chemistry Company

CF01 Termination of patent right due to non-payment of annual fee
CF01 Termination of patent right due to non-payment of annual fee

Granted publication date: 20070131

Termination date: 20180614